MET pathway as a therapeutic target

Journal of Thoracic Oncology

Volumn 4, Issue 4, 2009, Pages 444-447

  Kim, Eric S ^a   Salgia, Ravi ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

MET pathway; Therapeutic target; Thoracic tumorigenesis

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMG 102; ANISOMYCIN; ANTINEOPLASTIC AGENT; ARQ 197; DOCETAXEL; GEFITINIB; GELDANAMYCIN; MESENCHYMAL EPITHELIAL TRANSITION FACTOR RECEPTOR TYROSINE KINASE; MGCD 265; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SGX 523; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; XL 184; XL 880; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN;

ADENOCARCINOMA; ANGIOGENESIS; CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; CARCINOID; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LARGE CELL CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; METASTASIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 67649393456     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819d6f91     Document Type: Article

References (48)

1. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804. (Pubitemid 21926175)
2. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003. (Pubitemid 21924039)
3. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316-325. (Pubitemid 47509708)
4. Maestrini E, Tamagnone L, Longati P, et al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci U S A 1996;93:674-678. (Pubitemid 26041148)
5. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007;9:102-108. (Pubitemid 46332381)
6. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999;31:1357-1362.
7. Hammond DE, Urbe S, Vande Woude GF, Clague MJ. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001;20: 2761-2770. (Pubitemid 32549833)
8. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12:3657-3660. (Pubitemid 44000247)
9. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996;384: 173-176. (Pubitemid 26386473)
10. Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994;9:2019-2027. (Pubitemid 24194169)
11. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/ scatter factor receptor family. Cell 1994;77:261-271. (Pubitemid 24138623)
12. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991;11:1793-1803. (Pubitemid 21895545)
13. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007;97:368-377. (Pubitemid 47196754)
14. Sachs M, Brohmann H, Zechner D, et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol 2000;150:1375-1384. (Pubitemid 30728909)
15. Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene 1999;18:3399-3406. (Pubitemid 29286986)
16. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000;19:2212-2223. (Pubitemid 30307187)
17. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 2001;98:247-252. (Pubitemid 32095895)
18. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391:285-288. (Pubitemid 28099015)
19. Chen HC, Chan PC, Tang MJ, Cheng CH, Chang TJ. Tyrosine phos-phorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation. J Biol Chem 1998;273:25777-25782. (Pubitemid 28475804)
20. Gual P, Giordano S, Williams TA, Rocchi S, Van Obberghen E, Comoglio PM. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000;19:1509-1518. (Pubitemid 30175672)
21. Lai JF, Kao SC, Jiang ST, Tang MJ, Chan PC, Chen HC. Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells. J Biol Chem 2000;275:7474-7480.
22. Lamorte L, Kamikura DM, Park M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 2000;19:5973-5981. (Pubitemid 32039372)
23. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)
24. Jagadeeswaran R, Surawska H, Krishnaswamy S, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008;68:132-142.
25. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008;44:641-651.
26. Gille J, Khalik M, Konig V, Kaufmann R. Hepatocyte growth factor/ scatter factor (HGF/SF) induces vascular permeability factor (VPF/ VEGF) expression by cultured keratinocytes. J Invest Dermatol 1998; 111:1160-1165. (Pubitemid 29115191)
27. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-12723. (Pubitemid 37339965)
28. Rosen EM, Grant DS, Kleinman HK, et al. Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol 1993;47:227-234.
29. Furge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001;98:10722-10727. (Pubitemid 32878688)
30. Moghul A, Lin L, Beedle A, et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 1994;9:2045-2052. (Pubitemid 24194172)
31. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488. (Pubitemid 40270177)
32. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-6281.
33. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73. (Pubitemid 27198158)
34. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
35. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104: 20932-20937.
36. Kuhn DE, Martin MM, Feldman DS, Terry AV Jr, Nuovo GJ, Elton TS. Experimental validation of miRNA targets. Methods 2008;44:47-54.
37. Ross JS, Carlson JA, Brock G. miRNA: the new gene silencer. Am J Clin Pathol 2007;128:830-836. (Pubitemid 350133996)
38. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620-627. (Pubitemid 34193985)
39. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6. (Pubitemid 28037188)
40. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60:6737-6743.
41. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 2007;24:1910-1918. (Pubitemid 47389247)
42. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-6742. (Pubitemid 350206811)
43. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21:4885-4893. (Pubitemid 34888333)
44. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007;67:3529-3534. (Pubitemid 46762132)
45. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-5393. (Pubitemid 39005814)
46. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-3322.
47. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-4417. (Pubitemid 46815090)
48. Abidoye O, Murukurthy N, Salgia R. Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials 2007;2:143-147. (Pubitemid 46773882)